We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

By LabMedica International staff writers
Posted on 31 Aug 2014
A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells.

The recognition of pathogen-infected cells by the immune system's NK cells is controlled by inhibitory and activating receptors. More...
Investigators at the Hebrew University of Jerusalem (Israel) had shown previously that among the activating NK cell receptors, the natural cytotoxicity receptors NKp44 and NKp46 interacted with the viral hemagglutinin (HA) protein expressed on the cell surface of influenza-virus-infected cells. The interaction between NKp44/NKp46 and viral HA was sialic-acid dependent, and the recognition of HA by NKp44 and NKp46 led to the elimination of the infected cells.

In the current study, which was published in the August 1, 2014, issue of the Journal of Infectious Diseases, the investigators demonstrated that the influenza virus developed a counter-attack mechanism based on the virus' neuraminidase (NA) protein. The NA enzyme removed HA sialic acid and prevented the recognition of the virus by the NKp44 and NKp46 receptors. This lack of recognition resulted in reduced elimination of the infected cells by NK cells.

Understanding the NA/HA interaction and its influence on NK cell behavior is expected to lead to the development of new approaches for treating influenza.

Influenza is a major global health problem causing approximately three to five million cases of severe illness and leading to between 250,000 and 500,000 deaths worldwide. “It is thus urgent to develop new drugs for fighting influenza infection, which requires an understanding of the virus's life cycle and its interaction with the host’s immune system,” said first author Yotam Bar-On, a research student in immunology and oncology at the Hebrew University of Jerusalem.

In recognition of the significance of his research, Yotam Bar-On was recently awarded the prestigious Kaye Innovation Award. This award was established by the prominent British pharmaceutical industrialist Isaac Kaye to encourage faculty, staff, and students of the Hebrew University of Jerusalem to develop innovative methods and inventions with good commercial potential which will benefit the university and society.

Related Links:

Hebrew University of Jerusalem



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.